Skip to main content
. 2021 Jul 19;16(7):e0254116. doi: 10.1371/journal.pone.0254116

Table 1. Tryptophan/Kynurenine pathway metabolite concentrations in T1D patients.

Patient Trp Kyn KA AA XA PA QA 3OHAA mg/dL mEq/L mg/mL Age Disease Gender Race Diastolic
uM nM nM nM nM nM nM Peak Area Glucose CO2 BUN years Duration Abnormal
1A 39.4 307.5 862.8 186.3 639.3 1209.0 667.8 9.57E+05 595 <5 26 13.25 1d M C N
1C 66.3 1173.6 1299.8 283.3 711.3 1183.4 724.2 6.31E+05
2A 41.5 411.1 530.2 294.6 370.3 890.0 510.0 6.14E+05 416 <5 22 14.42 5y F AA Y
2B 51.4 633.6 466.1 128.2 432.4 831.8 618.8 1.52E+05
2C 45.2 362.8 626.9 172.6 390.3 1087.2 571.8 2.03E+05
3A 52.7 429.5 530.4 327.4 430.3 1402.4 516.7 8.43E+05 338 5 18 13.58 9y F C Y
3B 94.3 713.6 658.0 279.9 782.3 1349.3 553.5 3.46E+05
3C 56.3 793.7 461.8 264.1 447.8 1102.2 649.6 2.94E+05
4A 44.0 737.0 671.3 296.0 386.6 1139.6 450.2 3.33E+05 441 7 20 16.92 3y M AA Y
4B 67.0 1091.5 735.0 266.1 537.2 1697.8 646.7 2.22E+05
4C 41.8 750.7 788.1 242.8 329.9 1272.0 543.2 2.37E+05
5A 41.1 203.7 555.0 223.9 351.6 900.5 526.7 9.12E+05 299 5 14 11.42 3y M AA N
5B 56.1 365.6 582.9 271.5 452.7 1316.7 454.0 4.84E+05
5C 46.7 438.2 506.8 269.3 354.2 811.6 475.2 3.21E+05
6A 44.3 516.1 986.9 325.4 388.3 983.0 473.1 1.01E+06 845 7 42 10.08 1d F C N
6B 52.3 702.5 626.4 188.9 424.0 926.7 513.4 2.65E+05
6C 69.9 459.6 889.7 303.9 601.9 1263.3 435.9 5.11E+05
7A 60.2 454.5 563.2 146.0 564.0 898.6 549.8 4.83E+05 479 7 25 16.92 1y M AA N
7B 50.7 543.0 553.1 286.8 441.9 837.9 645.4 6.38E+05
7C 45.2 408.9 629.5 229.0 374.5 661.7 511.8 2.44E+05
8A 28.3 258.9 467.4 177.9 238.8 677.4 476.4 2.06E+05 322 11 15 16.33 1d F AA Y
8B 36.8 315.3 440.8 127.1 316.3 795.7 537.5 2.12E+05
8C 34.9 313.2 585.2 97.0 296.2 842.3 553.5 1.77E+05
9A 25.5 295.0 376.0 141.8 210.2 516.9 365.9 2.70E+05 541 7 18 13.08 1d M C N
9B 36.2 291.4 298.7 103.3 286.4 434.1 465.6 1.12E+05
9C 37.0 226.6 888.6 164.6 361.7 998.3 388.0 6.87E+05
10A 25.3 379.3 549.1 148.9 249.5 759.2 388.2 5.36E+05 552 <5 15 14.33 12y F AA Y
10B 36.2 280.1 562.5 218.7 271.3 702.6 359.9 2.27E+05
10C 31.9 682.9 452.2 179.9 250.9 856.7 469.0 2.93E+05
11A 19.3 185.8 308.0 153.8 207.7 470.6 434.1 2.32E+05 576 6 14 11.58 1d F AA Y
11B 31.0 314.1 413.4 169.4 243.9 969.9 336.9 3.85E+05
11C 34.7 305.8 401.4 93.3 254.7 829.6 494.0 3.09E+05
12A 31.2 918.2 815.3 177.4 350.0 1222.4 372.9 5.97E+05 260 7 31 16.25 6y M AA Y
12B 48.4 367.6 445.2 59.6 414.4 1014.0 487.7 5.88E+05
12C 38.3 356.1 535.1 98.4 338.3 924.5 446.2 7.00E+05
13B 32.7 365.1 470.1 130.4 274.6 868.2 430.7 4.82E+05 458 <5 12 15.25 7y F C N
13C 34.2 395.8 300.6 158.1 262.8 875.3 379.6 4.10E+05
14A 36.2 430.8 262.2 105.5 262.2 562.9 449.4 1.15E+05
14B 29.3 296.8 475.9 203.1 227.2 1057.5 366.4 4.00E+05 550 6 22 9.67 1d F AA N
14C 29.0 258.9 362.1 128.6 233.9 955.8 405.1 2.84E+05
15A 23.9 412.7 505.4 164.3 237.3 676.1 349.3 4.31E+05 560 6 18 15.5 13y F AA Y
15B 32.1 288.8 404.3 127.8 268.0 745.5 480.4 2.42E+05
15C 36.3 361.7 448.1 139.4 290.8 631.7 369.2 5.11E+05

Concentrations of tryptophan/kynurenine pathway metabolites tryptophan (Trp), kynurenine (Kyn), quinolinic acid (QA), kynurenic acid (KA), 3-OH-anthranilic acid (3OHAA), anthranilic acid (AA), picolinic acid (PA), xanthurenic acid (XA) in 15 patients at three time points, Time A at 6-12hours, Time B at 2 weeks and Time C at 3 months after the beginning of treatment. The patient glucose levels, urea nitrogen (BUN), CO2 concentration, age, disease duration, gender, race (African American = AA and Caucasian = C) and diastolic abnormality is also listed.